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Abstract
The most common presentation of nephrolithiasis is idiopathic calcium stones in patients without 
systemic disease. Most stones are primarily composed of calcium oxalate and form on a base of 
interstitial apatite deposits, known as Randall’s plaque. By contrast some stones are composed 
largely of calcium phosphate, as either hydroxyapatite or brushite (calcium monohydrogen 
phosphate), and are usually accompanied by deposits of calcium phosphate in the Bellini ducts. 
These deposits result in local tissue damage and might serve as a site of mineral overgrowth. Stone 
formation is driven by supersaturation of urine with calcium oxalate and brushite. The level of 
supersaturation is related to fluid intake as well as to the levels of urinary citrate and calcium. Risk 
of stone formation is increased when urine citrate excretion is <400 mg per day, and treatment 
with potassium citrate has been used to prevent stones. Urine calcium levels >200 mg per day also 
increase stone risk and often result in negative calcium balance. Reduced renal calcium 
reabsorption has a role in idiopathic hypercalciuria. Low sodium diets and thiazide-type diuretics 
lower urine calcium levels and potentially reduce the risk of stone recurrence and bone diseas
Introduction
Kidney stones have increased in prevalence over the past 50 years in most countries, and as 
of 2010 the prevalence in the United States was 8.8%, compared with 5.5% in 19941. The 
prevalence is higher in men (10.6% among men compared with 7.1% among women in the 
recent United States data) and in Causasians compared with Africans1, and at least 35% of 
first time stone formers will have one or more recurrences. As stone disease often affects 
adults during their working years, the costs of stone disease include both medical 
intervention as well as time lost from work, school, or family care, and exceeds $10 billion 
dollars yearly in the United States2. The majority of stones (85%) contain primarily calcium 
oxalate (CaOx) admixed with some calcium phosphate (CaP) in the form of apatite or 
brushite, or occasionally uric acid; less commonly they may be composed primarily of CaP3. 
Non-calcium stones may be made of uric acid or cystine. Although many systemic diseases, 
such as primary hyperparathyroidism, bowel disease and renal tubular acidosis, can result in 
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calcium stone formation, the majority of calcium stones are found in people with no 
systemic illness. Many idiopathic patients who form calcium stones have metabolic 
abnormalities that can be detected by 24 hour urine analysis but are not considered to be 
systemic disease. Among the most common of these abnormalities is idiopathic 
hypercalciuria4. This disorder has been shown to be heritable, but is also influenced by 
environmental factors such as diet.
Since most kidney stones seen in clinical practice will be idiopathic calcium stones, and the 
commonest predisposing factor in these patients is hypercalciuria, the remainder of this 
review will concentrate on these patients, and discuss the mechanisms of idiopathic calcium 
stone formation as well as potential therapeutic strategies to correct hypercalciuria and 
reduce the risk of stone formation.
Patient phenotyping
A traditional method of phenotyping patients with calcium stones includes analysis of stone 
crystal composition as well as consideration of the presence or absence of established 
diseases that could cause stones. Among idiopathic patients, those whose stones are 
predominantly composed of CaOx (>50%) are considered to be a separate group from those 
whose stones are predominantly composed of calcium phosphate (CaP) crystals such as 
apatite or brushite5.
Modern endoscopy techniques enable direct renal papillary visualization during stone 
surgery and this has added papillary morphology to our phenotyping. Direct biopsy of the 
papillum enables additional refinement of the stone phenotype but is unlikely to be used for 
patient care as it is a research tool at this time.
Formation of idiopathic calcium stones
A key question regarding calcium stone formation is whether these stones form in contact 
with renal tissue or in the bulk urine without a direct tissue interaction. The available 
evidence demonstrates that calcium stones do form in contact with tissue, but proof that 
formation in urine can also occur is lacking. If the predominant way in which stones form is 
on anchored sites in the renal papillae, then the nature of those sites, and the way in which 
they occur, is an important part of the story of stone pathogenesis.
Growth on interstitial apatite deposits
Clinically important CaOx stones can form as overgrowths on interstitial apatite deposits 
known as Randall’s plaque. During percutaneous or ureteroscopic stone removal surgery, 
CaOx stones — including stones of clinically significant size — can be seen growing on 
human renal papillae (Figure 1). These stones can be detached only with some effort, 
whereupon an attachment site can be seen on the stone. In some cases, the corresponding 
regions of attachment on the renal papillae are also visible to the surgeon.
In a study that included nine patients with idiopathic CaOx stones (those with systemic 
disease were excluded) we found that 78% of 115 stones visualized at surgery were attached 
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to papillae, and of these 90% were attached over plaque, which itself occupied ≤5% of the 
papillary surface area.6 In a separate study of unattached stones in the same patients, 
evidence of an attachment site — an apatite deposit — was present on all of these stones, 
suggesting an origin on plaque.7
The percentage of patients without hypercalciuria who form CaOx stones on plaque is 
unknown. In an unselected population of 78 patients who underwent percutaneous 
nephrolithotomy (PNL), Linnes et al. identified 37 patients (of whom 26 were female) with 
idiopathic CaOx stones.8 These patients were not remarkably hypercalciuric (mean 24 h 
urinary calcium level of 210 mg). Although the researchers reported a mean plaque surface 
area coverage of 3.6%, they did not indicate whether or not the CaOx stones were found on 
plaque. In a subsequent study that included 42 idiopathic patients with CaOx stones who 
underwent PNL, abundant plaque (>5% surface area coverage) was found in 10 patients (of 
whom six were male).9 These patients had higher urinary calcium excretion (291 mg per 
day) than those with lower plaque abundance (of whom eight were male; 187 mg per day). 
In a third study, these researchers found no evidence of increased plaque or urine calcium in 
95 patients who formed idiopathic CaOx stones (of whom 42 were male) compared with 19 
healthy individuals or 23 patients who formed uric acid stones.10
Although these studies from a single group of investigators do not report the location in 
which the stones were formed, analysis of stones by micro-CT, showed that those from 
patients with >5% plaque surface area coverage were more likely to show evidence of 
growth on plaque than those from patients with <5% plaque surface area coverage. Future 
surgical series will clarify the frequency with which stone growth on plaque can be 
documented using endoscopy.
Formation of stones on plaque can also be investigated via careful analysis of the stones 
themselves. In a large series of stones analyzed in a French laboratory using infrared 
spectroscopy and morphoconstitutional analysis, 34% of 30,149 intact stones collected 
between 1989 and 2013 that were at least 85% CaOx showed evidence of having formed 
over Randall’s plaque11. Moreover, a marked increase in the frequency of nucleation of 
stones over plaque occurred between 1990 and 2010 in men and in women, particularly in 
young adults. Analysis of CaOx stones passed between 2009 and 2011 showed that among 
patients aged 20–29 years, approximately 60% of those passed by women and 50% of those 
passed by men had nucleated over plaque, compared with 20% of those passed by women 
and 25% of those passed by men aged ≥70 years. It is not possible to determine how many 
of these patients were idiopathic stone formers, but it is probable that the majority did not 
have systemic disease.
The phenomenon of CaOx stones growing on interstitial plaque has also been observed in 
patients with CaOx stones owing to primary hyperparathyroidism12, ileostomy13 and small 
bowel resection14 as well as in idiopathic patients whose stones are composed mainly of 
hydroxyapatite15 or brushite16. Patients who form idiopathic hypercalciuric CaOx stones are 
unique, however, because growth on plaque seems to be the only mechanism of stone 
formation and plaque is often the only renal tissue mineralization. In patients with systemic 
diseases and in patients who form hydroxyapatite or brushite stones, growth on plaque is 
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found in combination with a different kind of tissue mineralization: plugging of inner 
medullary and papillary collecting ducts with crystals of hydroxyapatite, brushite or CaOx, 
depending on the clinical condition17 (discussed below).
Plaque formation—The initial sites of plaque formation are the basement membranes of 
the thin limbs of the loops of Henle, in which plaque appears as microspherules of 
alternating organic and apatite crystal laminations (Figure 2)18. Subsequently, either by 
extension or additional formation, plaque appears in the papillary interstitium. Plaque that 
forms in this location is an amalgam of apatite crystals in an organic matrix that contains 
osteopontin19, inter-α-trypsin inhibitor heavy chain 320, and other molecules that have yet to 
be determined.
High resolution CT imaging of plaque within intraoperative tissue biopsy samples from 
patients with idiopathic CaOx stones supports the idea of plaque extension from the thin 
limbs of the loops of Henle into the interstitium. In some images mineral can be seen 
forming along the long axis of a thin limb and merging smoothly with the plate-like 
interstitial plaque21. An analysis of papillary biopsy samples from 12 patients with 
idiopathic CaOx stones who underwent PNL identified plaque in all patients22. The plaque 
deposits were located in the interstitium and in the basement membrane of the tubular 
epithelium; the specific tubule segments involved were not reported. X-ray dispersive 
microanalysis showed that the deposits were composed of calcium and phosphate. In the 
interstitium, plaque deposits were mixed in with long thin fibers of collagen. The collagen 
fibers act as a scaffolding for the heterogeneous nucleation of CaP crystal as is seen in bone 
formation. These findings are confirmatory of our work.
The mechanisms that lead to the formation of interstitial plaque are unknown. A role of 
osteogenesis can be excluded because the critical bone genes RUNX2 and SP7 (also known 
as Osterix) were not expressed at sites of plaque in biopsy samples from nine patients with 
idiopathic CaOx stones23. By contrast, these genes were expressed in samples from 10 of 12 
patients with medullary sponge kidney disease23. The rather primitive papillary interstitial 
cells of patients with medullary sponge kidney do express RUNX2 and SP7, but the sites of 
expression are never the sites of mineral deposition. In patients with medullary sponge 
kidney, tiny stones can be found within dilated cystic terminal collecting ducts, but bone 
genes are not expressed at these sites.
We have observed that plaque coverage is a direct function of urine calcium excretion and an 
inverse function of urine pH and urine volume24. The mechanism by which urine calcium 
influences plaque formation may be related to renal tubule calcium reabsorption, which is 
decreased in stone formers with hypercalciuria. In particular, less calcium is reabsorbed in 
the proximal tubules of hypercalciuric stone formers, and more is delivered into the distal 
nephron. In the outer renal medulla, the vascular bundles are surrounded by a ring of thick 
ascending limb (TAL), which reabsorb calcium independently of water25. Calcium 
reabsorption in the TAL occurs mainly via the paracellular pathway26 and is driven by the 
transepithelial voltage difference between tubule lumen and the blood. As delivery of 
calcium to the TAL increases, reabsorption of calcium will tend to increase at the same rate, 
and as water is not reabsorbed the concentration of calcium within the vascular bundles will 
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increase. The descending vasa recta provide blood to the papillary capillary network that 
surrounds the thin limbs of the Loop of Henle in which plaque particles originate18. In 
principle increased proximal tubule delivery of calcium can, therefore, foster papillary 
plaque formation via a mechanism that we have called ‘vas washdown’27. This idea is 
compatible with what is known about plaque formation and renal physiology, but has yet to 
be proven experimentally. Supersaturations in the papillary interstitium that might affect 
plaque formation are largely independent of urine supersaturation, and these two types of 
supersaturation have different physiological causes.
Stoller and colleagues published arguments in favour of plaque genesis in the vasa recta, 
based on a study of cadaveric kidneys from 50 consecutive autopsies (including those of two 
individuals who were stone formers) in which papillary calcifications were radiologically 
detected in 57% of kidneys. Calcifications were found in the interstitium around tubules, and 
hypertension was the factor most strongly associated with such calcifications. Epidemiologic 
data linking stone formation to cardiovascular disease28 is cited as supporting the link to 
vascular disease, however histologic. evidence of a vascular site of origin is not evident in 
the majority of data on stone formation.
Two animal models of plaque formation have been produced: the NHERF-1 knockout mouse 
and a Tamm-Horsfall protein knockout mouse29. These models might prove to be a 
promising tool for further investigations into the pathogenesis of renal stones.
Stone formation over plaque—The process of CaOx stone formation over plaque 
cannot proceed unless the urothelium is compromised such that urine supersaturations can 
drive new crystal formation. The exposed surface of plaque is covered by a multilayered 
ribbon of alternating crystals and organic matrix, which faces the urinary space (Figure 2). 
Given that plaque is exposed to urine, the formation of an inner organic layer seems to be the 
first event. As this layer contains uromodulin (also known as Tamm-Horsfall protein) it must 
be of urine origin30.
Successive layers of hydroxyapatite nucleation and organic overlays create the multilaminar 
covering ribbon over the exposed plaque. The form of apatite in the ribbon is amorphous30;it 
does not have the exact structure of mature apatite and is rather in the form of tiny highly 
hydrated crystals. This form transitions to mature apatite at the urinary surface, which 
creates larger and more angular spiky crystals that build up the apatite–matrix base of the 
new stone. This base can be seen when stones are removed, or when unattached stones that 
have formed on plaque are carefully inspected31. The processes that convert the orderly 
laminations of the ribbon into the less regular and more bulky stone base, and convert apatite 
nucleation into CaOx nucleation to make up the bulk of the final stone, are unknown but 
presumably involve conversion of amorphous apatite into mature apatite.
Growth on tubule plugs
Plugging of Bellini ducts and inner medullary collecting ducts occurs in some patients with 
idiopathic CaOx stones8, 10, in virtually all patients with idiopathic brushite or 
hydroxyapatite stones15 and in all stone formers with systemic diseases such as primary 
hyperparathyroidism12, bowel diseases that include ileostomy13, small bowel resection14, 
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obesity bypass procedures32, renal tubular acidosis33, cystinuria34, and primary 
hyperoxaluria35. The location of Bellini duct plugs means that they are exposed to the tubule 
fluid on their proximal surface and the urine on their distal surfaces,. They can grow upward 
into the nephron and outwards into the bulk urine (Figure 3).
As plugs open onto the urinary space their distal ends are exposed to the supersaturations 
present in urine. These open ends often have overgrowths31, which are sometimes described 
as ‘microliths’. Although the hypothesis is attractive, no proof yet exists that plug 
overgrowths can increase in size to form clinically relevant stones. Plugging occurs within 
the renal epithelial compartments, causes obvious local injury, and is an integral part of the 
complex mineralization of the kidneys of patients who form stones.
Brushite stones—When brushite is present in stones it is usually the predominant crystal 
component, although stones may also contain some CaOx or apatite. Patients who form 
brushite stones show a much wider range of plugging severity that those who form other 
types of stones. Some papillae can be pristine apart from scattered interstitial apatite plaque 
(Figure 4), whereas others show tubule plugging with crystals, dilated Bellini duct openings, 
pitting and retraction16. Histological changes in plugged tubules include massive dilation, 
loss of epithelium and peritubular fibrosis. Plugging can be visualized during surgery; 
dilation of the Bellini duct is can be clearly seen, whereas plugged inner medullary 
collecting ducts are visible through the urothelium as elongate yellow cylinders that reflect 
crystal casts.
Apatite stones—These stones, which are particularly common among women, are 
composed predominantly (> 50%) of apatite; the remainder is CaOx. Much like patients who 
form brushite stones, patients who form apatite stones also form apatite plugs in their Bellini 
ducts and inner medullary collecting ducts (Figure 5). These plugs are generally smaller and 
far more numerous than those of patients who form brushite stones. In addition, interstitial 
calcifications of a kind not seen in other stone formers are also present15, which are irregular 
randomly distributed
laminar deposits of interstitial HA and matrix, without microspherules, and with a very high 
crystal-to-matrix ratio (Figure 5). The significance of these calcifications, which we have 
termed ‘novel interstitial plaque structures’, is not yet known.
As intratubular apatite deposits are so numerous, the tissue of some papillae can be almost 
completely replaced by crystal plugs, and nephrocalcinosis may be apparent on radiographs. 
In this respect the papillae are similar in appearance to those found in patients with distal 
renal tubular acidosis, and careful interpretation of blood and urine testing is necessary to 
avoid misdiagnosis.
Plug composition—Although few plugs have been harvested for study, their diversity is 
remarkable (Figure 3). A plug isolated from a patient with idiopathic hydroxyapatite stones 
had a tubule segment composed of hydroxyapatite and an overgrowth of hydroxyapatite and 
CaOx whereas a patient with idiopathic brushite stones produced a plug with a tubule 
segment that contained brushite, hydroxyapatite and CaOx and an overgrowth with a center 
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of CaOx and an outer region of brushite15. A plug from a patient with stones resulting from 
ileostomy had an hydroxyapatite tubule segment with a pure CaOx overgrowth31, and a plug 
from a patient with primary hyperparathyroidism had an intratubular portion of 
hydroxyapatite with an overgrowth of hydroxyapatite 31. In our analysis of 12 patients with 
medullary sponge kidney disease we found a single plug, which was composed of a mixture 
of hydroxyapatite and CaOX in the tubule and overgrowth regions23. We also found multiple 
examples of tiny (500 μm diameter) round microliths made of lamina of hydroxyapatite and 
CaOx in the dilated and pathological inner medullary collecting ducts of these patients. How 
these microliths form is unknown.
Cortical changes—As only ~350 Bellini ducts drain the nephrons of a single kidney25, 
one might expect to find changes in the cortical tissue of patients with substantial plugging 
in comparison to that of patients in whom plugging is not found. Among patients with 
idiopathic CaOx stones who did not have plugs, cortex (Figure 6) looked similar to that of 
people without kidney disease15. Cortex from patients who formed brushite or 
hydroxyapatite stones showed scattered regions of scarring and nephron loss15. Given this 
scattered distribution it is unsurprising that such scarring rarely results in a reduction in renal 
function15, 16, 36.
Remaining questions
We know from observation of human kidneys that growth on plaque occurs and is 
widespread among patients who form calcium stones, whether idiopathic or secondary to 
systemic disease. Tubule plugs give rise to overgrowths that resemble kidney stones in their 
composition, but overgrowths observed so far are much too small to produce clinical disease. 
The natural assumption is that these overgrowths increase in size and become clinically 
relevant stones, but this mechanism remains to be proven. We have not yet found stones of 
clinically important size attached to plugs, suggesting that overgrowths do not increase in 
size to form stones in this location. Such growth might occur in the crevasses of the calyces, 
but no method yet exists to test this hypothesis.
The frequencies with which plaque and plugging occur will gradually be defined as larger 
populations are studied in the future. It is important that such studies clearly document the 
locations in which stones are forming, so that mechanisms of stone formation can be 
clarified.
Formation in free solution is commonly suggested as a mechanism of kidney stone 
formation37, but proof that this mechanism occurs is lacking. Stones that grow from a plug 
overgrowth or form in the bulk urine might look the same. The organic stones, cystine and 
uric acid, might theoretically form in free solution, but no experimental test currently exists 
to prove this hypothesis in humans. The microliths of patients with medullary sponge 
kidneys are perhaps the most obvious candidates for formation in free solution23. These 
round, unattached, whorls of hydroxyapatite and CaOx form in the lumens of dilated inner 
medullary collecting ducts but no proof exists that they grow into clinically significant 
stones.
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Finally, the relationship between cortical changes in patients who form brushite or 
hydroxyapatite stones and clinically important renal disease is unknown. Some evidence 
supports an increased risk of chronic kidney disease among patients who form stones38, 
which perhaps reflects our findings of cortical scarring in patients with inner medullary duct 
plugs, but further research is needed.
Formation of crystals
Role of supersaturation
Supersaturation is accepted on physical chemistry grounds as the prime source of free 
energy that drives the nucleation and growth of crystals39, 40. The supersaturation of urine 
with respect to the relevant crystal phases in stones can be estimated using a well-established 
set of measurements41, 42 and computer programs that calculate the simultaneous ion 
equilibria in solution of these stone salts, comparing them to the known thermodynamic 
solubility constants to derive estimates of supersaturation. [ref: Finlayson B. “Calcium 
Stones: Some Physical and Clinical Aspects”, in Calcium Metabolism in Renal Failure and 
Nephrolithiaisis, David DS, ed. John Wiley and Sons, New York 1977. pp 337–382]. At least 
two supersaturations are always of concern in patients who form calcium stones: CaOx and 
CaP. Even patients who form the purest idiopathic CaOx stones over plaque and have no 
tubule plugging require that hydroxyapatite form as the base of these stones30. In almost all 
patients with idiopathic calcium stones who also have tubule plugging, hydroxyapatite and 
brushite as well as CaOx can be found in plugs and stones14, 31. Whether or not specific 
attempts to regulate both CaP and CaOx supersaturation will lead to improved stone 
prevention could perhaps be evaluated in future trials. Given the current lack of trial 
evidence, and little obvious risk, monitoring and controlling both supersaturation values 
seems prudent as a clinical approach.
With perhaps the exception of minor oxalate secretion in some patients who form idiopathic 
calcium stones43, the main stone crystal components — calcium, phosphate and oxalate — 
are filtered and reabsorbed so supersaturation of urine cannot exceed that of blood except 
through water extraction along the nephron. Urine supersaturation is essentially the stored 
energy produced by water extraction, which can be dissipated by driving phase change40. 
This well established paradigm emphasizes the remarkable power of simple hydration; by 
reducing water reabsorption, fluids reverse the primary engine of crystallization.
Inhibition by urine proteins
Modern techniques have identified >1000 urine proteins44, 45, many of which have long 
been known for their abilities to kinetically retard calcium crystal nucleation, growth and 
aggregation46, 47. Stones contain many such proteins, presumably because their crystals have 
adsorbed them from urine as they formed48.
Urine proteins are the main reason why urine can remain stable for days despite 
supersaturation; simple salt solutions with a similar level of supersaturation are unstable40. 
Essentially, the proteome alters the link between supersaturation and crystallization. In 
simple solutions supersaturation and crystallization are tightly related, whereas in urine 
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supersaturation is necessary to achieve crystal formation and prevent crystal dissolution, but 
a particular level of supersaturation cannot be predicted to result in new crystal formation 
due to the presence of an unknown number of inhibitors. The idea of comparing the urine 
supersaturation of healthy individuals and patients who form stones, and identifying a level 
of supersaturation that will reliably distinguish between the two groups is, therefore, flawed.
Crystal interactions
Brushite—In urine, when nucleation is induced in vitro by addition of calcium, the initial 
phase that forms is usually brushite49. Oxalate can bind to calcium atoms on the surface of 
brushite and begin to form CaOx crystals. As CaOx crystals are less soluble than brushite 
they are able to cannibalize the brushite provided the solution is supersaturated with respect 
to CaOx40, 50. In the presence of osteocalcin40, hydroxyapatite can begin to form on the 
surface of brushite with liberation of a proton as the monohydrogen phosphate of brushite is 
taken up into the hydroxyapatite lattice as trivalent negative phosphate ions.
As a result, brushite is usually a transient phase in urine, and one would not generally expect 
to find brushite in kidney stones. Indeed, large series of stones have reported that only 
approximately 1% contain brushite51, 52.. Mechanisms of brushite persistence might involve 
specific patterns of the urine proteome, but this hypothesis has not yet been investigated.
Citrate—Citrate ions bind calcium53 so reduce the amount of calcium that is available to 
bind with oxalate or phosphate and thereby lower supersaturation with respect to all of the 
calcium stone crystals54. Binding of citrate to brushite crystals widens their growth plates so 
slows their growth and inhibits the formation of new brushite as oxalate and apatite use it as 
a source of ions40. Citrate also binds to growth ridges on CaOx crystals and slows their 
growth40, 55.
It is important to note that brushite crystal cannibalization has been shown to occur in vitro 
rather than in whole urine. Likewise the effects of citrate on crystals have only been proven 
in simple solutions. All crystals follow the same laws of physics, but given the huge urine 
proteome with its crystal active molecules, the interactions of crystals in urine and with 
citrate might not be fully predicted by in vitro studies.
Idiopathic hypercalciuria
It is the molarity of calcium, oxalate, phosphate, and citrate, along with urine pH, that 
mainly determine SS for CaOx and brushite, and molarities reflect the relationship between 
solute excretion and urine flow. Hypercalciuria is associated with higher levels of 
supersaturation at any given urine flow when compared to normal calcium excretion. 
Idiopathic hypercalciuria is familial [ref], found in up to 50% of idiopathic calcium stone 
formers and is often of considerable magnitude, so it has long occupied the attention of 
clinicians and scientists56. Increases in oxalate excretion and reductions in citrate excretion 
might well be of equal importance to hypercalciuria in terms of stone formation but are not 
discussed in this Review.
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Definition
Although hypercalciuria can result in renal stones and probably also bone mineral loss and 
fractures57, it is not a disease per se, but rather represents the upper tail of a continuous 
distribution, similar to height, weight or blood pressure.
As urine calcium excretion is a continuously distributed variable it is not ideal or even 
reasonable to choose a single cut-off point to define ‘normal’ levels. Rather, similar to blood 
pressure and body weight, urine calcium excretion should be considered a graded risk factor, 
and the calcium excretion rate of the individual patient should be considered along with 
other factors that affect urine supersaturation when making treatment decisions.
Data from epidemiological studies enable correlation of various levels of urine calcium 
excretion with the relative risk of stone formation58. For both sexes, the lower 95% 
confidence interval (CI) for a relative risk ratio for stone formation of >1 (that is, increased 
risk) is present at urine calcium levels of about 200 mg daily. This value could, therefore, be 
considered the lower limit of clinical hypercalciuria and the threshold for consideration of 
treatment measures aimed at lowering urine calcium excretion. Of course, being a graded 
risk factor, lowering of urine calcium levels to <200 mg might be appropriate in certain 
patients, such as those with persistent stone formation.
Mechanisms
Increased gut calcium absorption—In individuals with normal urinary calcium 
excretion, intestinal calcium absorption rises with dietary intake; on average around 25% of 
dietary calcium is absorbed in both men and women. By contrast, around 30% of dietary 
calcium is absorbed in patients with idiopathic hypercalciuria.59–70
Gastrointestinal calcium absorption is mediated by both epithelial transport and passive 
paracellular absorption71. The increased fraction of dietary calcium that is absorbed in 
patients with idiopathic hypercalciuria suggests that epithelial transport of calcium is 
increased in these patients. As the vitamin D hormone system increases epithelial calcium 
transport, increased calcium absorption in patients with idiopathic hypercalciuria could be 
the result of increased serum calcitriol levels, increased tissue vitamin D receptor expression 
or a combination of these factors. Indeed, the serum calcitriol levels of individuals with 
idiopathic hypercalciuria are generally higher than those of individuals with normal urinary 
calcium excretion72, suggesting that activation of the vitamin D hormone system might be 
an integral component of idiopathic hypercalciuria73. Inbred hypercalciuric rats have normal 
serum calcitriol levels, but high intestinal and renal vitamin D receptor expression and 
enhanced intestinal epithelial calcium absorption74.
Increased renal calcium loss—Two mechanisms exist by which renal calcium losses 
might be increased in patients with hypercalciuria: increased filtered load of calcium or 
reduced tubule calcium reabsorption. Under controlled dietary conditions, the serum 
concentrations of ultrafilterable calcium in patients with idiopathic hypercalciuria and 
individuals with normal urinary calcium levels overlap both fasting and fed 75. Filtered loads 
of calcium do not differ, and show no tendency to increase with meals in either group75. By 
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contrast, the urinary calcium levels of patients with idiopathic hypercalciuria exceeds that of 
normal individuals during fasting, and increased greatly above normal levels in the fed 
state76. This increase occurs because of a marked fall in overall tubule calcium 
reabsorption75.
Although the levels of insulin and parathyroid hormone both change with meals and can 
differ between individuals with and without hypercalciuria, a decrease in calcium 
reabsorption in these groups occurs at overlapping levels of these hormones77. Likewise, the 
levels of fractional sodium reabsorption overlap in these the two groups75. Tubule calcium 
reabsorption in patients with idiopathic hypercalciuria and those with normal calcium 
excretion, therefore, differs independently of insulin levels, parathyroid hormone levels and 
sodium handling77, 78.
The delivery of calcium out of the proximal tubule into more distal nephron segments can be 
calculated using endogenous lithium clearance as a marker for proximal tubule reabsorption. 
Using this technique we found that distal calcium delivery was increased in patients with 
idiopathic hypercalciuria compared with individuals with normal calcium excretion79. This 
finding indicates that the proximal nephron segments contribute to the increase in urine 
calcium excretion in these patients.
Bone mineral balance
Most patients with idiopathic hypercalciuria seem to have increased intestinal calcium 
absorption coupled with decreased renal calcium reclamation. However, urinary calcium 
excretion often exceeds gut calcium absorption in balance studies, and in fact, when dietary 
calcium intake is very low, patients with idiopathic hypercalciuria can excrete more calcium 
than they ingest81.
These data suggest that idiopathic hypercalciuria will cause bone disease when patients are 
challenged with a low calcium diet for stone prevention81. Consistent with this hypothesis, 
many studies have shown reduced bone mineral density and an increased incidence of 
fractures among patients with idiopathic hypercalciuria57. This is one reason why low 
calcium diets are not advisable for treatment of stone formers with idiopathic hypercalciuria. 
As patients with idiopathic hypercalciuria seem to have a generalized alteration of both gut 
and renal calcium handling, and are at risk of bone loss, attempting to separate patients into 
those with primarily absorptive or renal hypercalciuria is not clinically useful.
Patient management
Management of supersaturation
The urine supersaturation of a patient who is actively forming new stones is clearly too high 
with respect to the crystals in the stones that are being formed. Our current stone treatments 
aim at decreasing urinary supersaturation with respect to the stone mineral by a significant 
margin, perhaps by half. Lowering urine supersaturation often requires multiple 
interventions, which may include increased fluid intake, dietary counseling, and 
medications. Interventions should be targeted at the factors which are most likely to be 
raising supersaturation in a given patient, uncovered by 24 hour urines done prior to 
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treatment. Depending on stone (and supersaturation) type, these could include inadequate 
urine volume, elevated urine calcium, oxalate, or uric acid, or low urine citrate. A general 
approach to stone prevention is outlined in Box 1. Although no trials have specifically 
investigated whether management of supersaturation is more effective than routine drug 
therapy without such management82 for prevention of stone formation, we believe that 
management of supersaturation is justified and clinical trials of such an approach are not 
unreasonable. Patients should always be followed up with 24 hour urine measurements 4–6 
weeks after treatment is initiated, to assess the success of treatment at lowering 
supersaturation. If supersaturation persists, treatment can be adjusted according to the 
persistent risk factors.
Box 1
Management of patients who form idiopathic calcium stones
• Daily fluid intake should be high (>3 l on average) to achieve at least 2 l of 
urine daily; fluid intakes ≥3.5 l daily to achieve urine volumes of ≥≥2.5 l daily 
are advisable with adjustments for higher fluid needs depending on work, 
climate, and lifestyle. Accurate measurement of urine volume during 
treatment is essential.
• In patients who are hypercalciuric, dietary calcium levels should be at least 
1,200 mg daily (calcium should be obtained preferably from food rather than 
supplements) and dietary sodium levels should be restricted to ≤ 1.5 g daily.
We suggest using thiazide diuretics when high urine volume and reduced sodium intake 
fail to reduce supersaturations to half of their original values, when this end point has 
been reached but new stones form, and in patients who are unable or unwilling to alter 
their fluid and sodium intake sufficiently to reduce stone risk.
• Urine citrate levels should be increased to >400 mg daily using potassium 
citrate or other oral potassium-based alkali.
• In patients with urinary citrate ≥400 mg daily or with calcium phosphate 
stones, the use of alkali supplements has not been specifically tested and 
theoretical considerations suggest a possible adverse effect in the latter 
instance.
Fluid intake
Levels of urine supersaturation vary with urine flow rate and food intake (figure 7), in both 
normal subjects and hypercalciuric calcium stone formers fed identical diets and studied 
over the course of a day. During fasting, supersaturations of CaOx and CaP increase steeply 
as urine flow rate falls below 100 ml/h (Figure 7)76. The relationship between 
supersaturation and urine flow is less regular for CaP than for CaOx because urine pH 
strongly influences CaP supersaturation52 but not CaOx supersaturation. However it is clear 
that fluid intake markedly decreases supersaturation for both stone salts. A urine flow of 100 
ml/h during fasting and overnight, and 125 ml/h when fed would be predicted to minimize 
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urine supersaturation. Given an estimate of 0.9 l per day (40 ml/h) insensible water losses83 
among patients who are not exposed to an extreme of climate, fluid intakes of 140 ml/h 
during fasting and overnight and 165 ml/h when fed would be expected to achieve this urine 
flow. Lifestyle habits, climate, working conditions, and the use of therapies that lower urine 
calcium or oxalate excretion might alter these requirements. Our calculations suggest an 
ideal fluid intake of about 3.5 l per day to reduce the risk of stone formation; however, an 
intake of this volume might not be practical. As patients might not accurately know their 
urine volumes, measurement during treatment is essential.
Validation of the importance of fluids is provided by a randomized trial of water intake done 
in 200 idiopathic calcium stone formers who had formed a single stone. After five years, 
12% of the treated patients, who increased their urine volume from 1068 ml at baseline to 
2061 ml during treatment, had a recurrent kidney stone, compared to 27% of the controls, 
whose baseline urine volume of 1008 ml did not change during the study (p=0.008). 
Supersaturations for both calcium oxalate and calcium phosphate decreased significantly in 
the treated arm.
Low sodium diet
Urine calcium excretion is linearly related to urine sodium excretion, in both normal subjects 
and stone formers, and lowering sodium intake can lower urine calcium. A number of 
controlled experiments have documented the effects of changes in dietary sodium intake on 
urinary calcium excretion in healthy individuals84–92 and in patients with idiopathic 
hypercalciuria87, 91–97. Moreover observational studies have shown changes in urine calcium 
levels in these groups when dietary sodium levels have changed spontaneously94, 98–100.
A study of men with idiopathic hypercalciuria and calcium stones compared the effects of a 
low calcium, low oxalate diet to those of a diet with 1,200 mg calcium, reduced sodium and 
oxalate protein101. In this study, 23 of 51 patients on the low calcium diet and 12 of 52 
patients on the reduced sodium and protein diet formed a new stone over 5 years (P <0.01). 
The relative contributions of the lowered sodium and protein intakes on stone formation 
cannot be determined. However, given its remarkable ability to lower urine calcium, a trial 
of low sodium diet alone versus thiazide might be justified.
No data are available on the effect of sodium on bone balance in patients with idiopathic 
hypercalciuria, but the findings of a study of dietary sodium and calcium intakes in 
menopausal women suggest that a reduced sodium diet might benefit bone balance in the 
setting of idiopathic hypercalciuria88. As expected, calcium absorption was higher in women 
who received high calcium diets than in those on low calcium diets and calcium balance was 
negative in the low calcium diet groups. In the low sodium, high calcium diet phase, bone 
balance became positive because calcium absorption was the same as for high sodium, high 
calcium diet, but fecal and urine calcium losses were reduced with reduced dietary sodium.
In patients who are hypercalciuric, dietary calcium should be ample (≥1200 mg) and dietary 
sodium should ideally be restricted to < 1.5 g (65 mmol) per day as recommended for the 
US adult population by the Centers for Disease Control and Prevention102. This low sodium 
diet has the potential to reduce urine calcium levels and possibly maintain or even increase 
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bone mineral stores. It is preferable to obtain calcium from foods rather than supplements, 
but if supplements are used they should be taken with meals.
Thiazide and thiazide-like diuretics
Thiazide diuretics lower urinary calcium excretion103 and have been used to prevent the 
formation of calcium stones104. The effectiveness of this therapy is presumed to arise from 
the hypocalciuric action of thiazide, although this hypothesis has not been rigorously tested.
Among a welter of shorter trials of thiazide diuretics for stone prevention, three stand out for 
being randomized controlled trials with a treatment period of 3 years. First, in 1984, Laerum 
et al. showed that treatment with hydrochlorothiazide (25 mg twice daily) reduced stone 
recurrence in patients with urolithiasis; 10 of 25 patients in the placebo group formed a new 
stone compared with only four of 23 patients in the hydroclorothiazide group (P <0.01)105. 
In 1988 Ettinger et al. reported that treatment with chlorthalidone (25 mg daily) reduced the 
recurrence of CaOx stones; 12 of 26 patients in the placebo group versus 4 of 28 patients in 
the treatment group formed a new stone (P <0.01)106. Finally in 1993, Borghi et al. showed 
that treatment with the nonthiazide diuretic indapamide (2 mg daily) reduced stone 
recurrence in patients with calcium nephrolithiasis and hypercalciuria; nine of 21 patients in 
the placebo group and only six of 43 patients in the treatment group formed a new stone 
during the treatment period (P <0.01)107. Although all three studies were limited by 
incomplete follow up of lost participants, and another randomized trial might be justified, 
these data suggest that thiazide is effective for stone prevention.
In four men, we performed a complete analysis of tubule reabsorption before and after 6 
months of treatment with chlorthalidone 25 mg daily108. Thiazide reduced urine calcium 
excretion, fractional calcium excretion, and fractional lithium excretion, indicating that its 
effect involves reduced distal delivery of calcium out of the proximal tubule. These results 
suggest that thiazide might not only reduce stone formation, but also formation of interstitial 
plaque, but this hypothesis remains to be tested experimentally.
Data from balance experiments has demonstrated that thiazide therapy can improve bone 
mineral balance in idiopathic hypercalciuric stone formers. We found that chlorthalidone 
therapy (25 mg daily for 6 months) lowered net intestinal calcium absorption to a lesser 
extent than urine calcium excretion, so net bone balance increased109. Additional studies 
have shown increases in BMD110 and reduction of fracture rates111 with thiazide agents. We 
tend to treat patients with thiazide diuretics when high urine volume and reduced sodium 
intake have failed to bring urine supersaturations to half of their original values, when this 
end point has been reached but new stones occur and in patients who cannot or will not alter 
their fluid and sodium intake sufficiently to reduce stone risk.
Potassium citrate
Given its multiple roles in calcium binding and as an inhibitor of the formation of all three 
types of common stone crystal species, citrate is theoretically an important defense against 
stone formation. Consistent with this hypothesis, reduced levels of citrate correlated with 
new onset of stones in long-term observational studies of men and women58. For both sexes, 
the upper 95% confidence interval for the relative risk ratio of becoming a stone former is <1 
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when citrate excretion is >400 mg daily; lower levels of citrate excretion confer 
progressively increased risk of stone formation58. Treatment with potassium citrate or 
another oral potassium-based alkali should, therefore, be used to increase urine citrate levels 
to >400 mg daily and reduce the risk of stone formation in patients with idiopathic calcium 
stones.
Oral citrate intake increases urine citrate levels by imposing an alkali load as the citrate is 
metabolized as citric acid112, 113. Perhaps as a mechanism of removing alkali without raising 
urine pH the kidneys reduce renal citrate reabsorption via effects on the main citrate 
transporter in the proximal tubule114. Urine bicarbonate excretion often increases in 
response to oral citrate intake, resulting in increases in urine pH and CaP supersaturation112.
Potassium citrate — or potassium alkali of any kind — lowers urine calcium excretion in 
patients who form stones115 or in patients with bone diseases116. This effect probably occurs 
because the alkali neutralizes chronic dietary acid load116. As metabolic acidosis decreases 
proximal tubule sodium reabsorption117, 118 via a number of mechanisms119, 120, reversing 
the chronic acid load from diet will likely increase sodium reabsorption, which will help to 
conserve filtered calcium and decrease calcium excretion. Distal effects of diet acid load and 
its reversal have not yet been studied in humans or proven in experimental models.
‘Calcium’ stones—Potassium citrate treatment has been shown to reduce the formation of 
new calcium stones, but no trial has specifically targeted patients who form CaP stones; the 
majority of participants in the published studies made CaOx stones. In the first of two 
double-blind randomized controlled trials, 16 of 20 patients in the placebo group who 
completed 3 years of follow-up formed a new calcium stone compared to five of 18 patients 
who received potassium citrate121. In the second trial122, 16 of 25 patients in the placebo 
group and two of 16 patients in the treatment group formed a new calcium stone after 3 
years of follow up. In both of these trials the reduction in stone formation with therapy was 
statistically significant. A third randomized controlled trial that was not double blinded 
showed no significant difference in stone formation between the study groups; six of 22 
patients in the placebo group and five of 16 patients in the treatment group produced new 
stones over 3 years.123 The difference from the other two trials is clearly the low rate of 
recurrence among the placebo patients.. In two randomized controlled trials that followed 
patients after shock wave lithotripsy, those treated with potassium citrate had lower rates of 
retained fragment growth and new stone formation than untreated controls after 12 months 
of follow up 124, 125
Brushite and apatite stones—The effect of potassium citrate on formation of brushite 
and apatite stones is unclear. On the one hand, inhibition of brushite and hydroxyapatite 
formation, reduction of urine calcium excretion, and reduction of free calcium ions in urine 
should reduce CaP supersaturation and formation of CaP stones. On the other hand, higher 
urine pH directly increases supersaturation with respect to brushite52, 115 and fosters 
hydroxyapatite formation by providing increased receptors to take up the protons that are 
liberated as brushite is converted to hydroxyapatite126. The effect of potassium citrate on the 
formation of brushite or hydroxyapatite stones has not yet been evaluated in a clinical trial. 
In the meantime, physicians who use citrate might mitigate the risk of stone formation by 
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closely monitoring the increases in urine pH, CaP supersaturation and citrate excretion after 
starting treatment, and adjusting treatment accordingly. If stone recurrence persists, use of 
citrate should be re-evaluated.
Conclusions
Many patients who form idiopathic calcium stones are hypercalciuric. Supersaturations of 
CaP and CaOx in the urine and local to the papillary interstitium foster the formation of 
interstitial apatite plaque, overgrowth of amorphous apatite on exposed plaque, and the 
formation of the main CaOx body of attached stones. Citrate and some urine proteins 
kinetically slow the process of stone formation, but plaque overgrowth might eventually 
create stones despite these inhibitors. Supersaturations also create tubule plugs but exactly 
how this process occurs and whether the tiny overgrowths found on plugs become clinically 
significant stones is unknown. Idiopathic hypercalciuria is a renal disorder that results from 
reduced tubule calcium reabsorption. Further research is needed to clarify whether activation 
of the vitamin D hormone system with abnormally high intestinal calcium absorption occurs 
secondary to calcium losses in patients with hypercalciuria or is a primary component of the 
renal disorder. Importantly, low calcium diets are inappropriate and can cause harmful losses 
of bone mineral in these patients. Despite the remaining questions, the available data suggest 
that high fluid intake, low sodium diet and treatment with potassium citrate and thiazide 
diuretics are practical and effective approaches for stone prevention in idiopathic patients.
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Key points
• Idiopathic calcium stones are always accompanied by mineral deposits: 
interstitial deposits of apatite in patients with calcium oxalate (CaOx) stones 
or calcium phosphate (CaP) plugs in those with CaP stones
• Overgrowth of CaOx stones on plaque depends on the formation of an initial 
CaP phase; urine saturations of CaP and CaOx might, therefore, be equally 
important
• Microliths form on the open ends of tubule plugs but proof that these can 
grow into clinically relevant stones is lacking
• Patients with tubule plugs who form CaP stones show varying degrees of 
cortical fibrosis and nephron loss
• Trial data support the use of high fluid intake, potassium citrate, thiazide 
diuretic agents and a reduced sodium diet for prevention of recurrent calcium 
renal stones. [
• As idiopathic hypercalciuria arises from reduced renal tubule calcium 
reabsorption and is associated with negative calcium balance and bone 
disease, management with a low calcium diet is contraindicated
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Figure 1. Interstitial plaque and corresponding attachment site on a CaOx stone
a | Digital endoscopic image of a 3 mm CaOx stone attached to a papillum before stone 
removal by percutaneous nephrolithotomy. Several sites of interstitial plaque (arrowheads) 
are visible as well as blood vessels (arrows) that were used for image orientation. b | 
Following stone removal the papillum was reimaged — an overlay showing the sites of 
interstitial plaque and blood vessels after stone removal has been placed over the original 
endoscopic imagec | “Ghosted” CT image of the detached stone showing a site of calcium 
phosphate (arrowheads) on the papillary surface of the stone. The insert shows a light 
microscopic image of the papillary surface of the detached stone with the site of calcium 
phosphate (arrow). d | The site of calcium phosphate on the papillary surface of the stone 
(arrows) aligns with a region of interstitial plaque with a central blood spot (arrow) on the 
papillium, which is presumably the site of stone attachment. The insert shows the urinary 
surface of the detached stone.
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Figure 2. Sites of interstitial plaque in idiopathic CaOx stone formers
a | Endoscopic image showing irregular whitish regions of interstitial plaque covering the 
papillary tip. b | A biopsy from this region showing black Yasue-stained material (arrow) 
within the interstitial space of the inner medulla. c | Light microscopy and d | transmission 
electron microscopy images showing regions of plaque in the basement membrane of the 
thin loops of Henle only, suggesting that plaque originates at this site. e | The plaque is 
composed of laminated spheres with up to nine alternating light (hydroxyapatite) and dark 
(matrix) layers. f | Micro CT image of plaque that has filled the interstitium and generated 
islands that encompass nearby tubules with no evidence of intraluminal deposits. g | 
Transmission electron microscopy imageshowing a multilayered ribbon-like structure 
separating a region of interstitial plaque (lower right) from an overgrowth of developing 
stone (upper left). In the thickest region of the white lamina of the ribbon (insert), tiny thin 
spicules run perpendicular to the surface adjacent to voids containing tightly packed crystals 
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(small arrows). Numerous small crystals have grown into the outer border of the ribbon 
(asterisk) and merged with large crystals within the urinary space at the developing 
overgrowth. The double arrows indicate a large in-growing crystal.
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Figure 3. Bellini duct plugs with overgrowths in patients who formed calcium stones
a | Sites of crystalline deposits that form plugged Bellini ducts (BD) with an overgrowth 
region protruding into the urinary space. b | Endoscopic image of a plug (arrow) protruding 
from a dilated BD (arrowheads). BD plugs with overgrowths visible by light microscopy and 
micro-CT from c | a patient with idiopathic hydroxyapatite stones, d | a patient with 
idiopathic brushite stones e | a patient with ileostomy, f | a patient with primary 
hyperparathyroidism and g | a medullary sponge kidney. The curved, dotted lines divide the 
BD plugs from the overgrowth regions.
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Figure 4. Renal papilla of a patient who formed brushite stones
a | Endoscopic images of all ten papilla. The numbering corresponds to the x-ray image of 
the collection system. Papilla 1, 6, 7 and 10 show severe morphological changes including 
pitting (large arrows), flattening, plugs (black asterisk, papilla 7) and yellow plaque. Papilla 
2, 3, 5 and 8 show small pits (white asterisks) whereas papilla 4, 7 and 9 show small sites of 
interstitial plaque (double arrows). b | Scattered inner medullary collecting ducts (IMCDs) 
and Bellini duct (BD) filled with yellow crystalline deposits that have dilated the tubular 
lumens (arrow) and protrude from the opening of the BD (asterisk). Small sites of interstitial 
plaque are also visible (double arrows). c | Sites of yellow plaque (arrows) in the lumens of 
IMCD (asterisk in insert) just beneath the urothelium (arrow in insert) and near sites of 
interstitial plaque (double arrows). d | showing extensive injury in the lining cells of IMCDs 
clogged with mineral deposits (arrows). Regions of extensive interstitial fibrosis surround 
the plugged IMCDs (double arrows) and entrapped and injured adjacent thin loops of Henle 
(asterisk). Giant cells (arrowheads) were occasionally found near damaged IMCDs.
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Figure 5. Renal papilla of patients who formed idiopathic apatite stones
Patients who form apatite stones can be categorized into two groups on the basis of 
endoscopy images: those with a | normal appearing papillae and those with b | severe 
changes that resemble those of patients who form distal renal acidosis stones. Panel a | 
shows a papilla with three separate attached stones (double arrowheads) and no yellow 
plaque or Bellini duct plugs, whereas panel b | shows a papilla with numerous regions of 
yellow plaque (arrows) and a large BD plug (asterisk). Light microscopy images showing c | 
novel interstitial plaque structures (arrow) — a form of plaque that is unique to patients who 
form apatite stones — characterized by irregular, large and randomly distributed laminar 
structures of hydroxyapatite crystal and matrix, and d | numerous plugged inner medullary 
collecting ducts surrounding an area of extensive interstitial fibrosis in a papilla with severe 
changes. Micro-CT images of tubular deposits in biopsy samples from e | a normal 
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appearing papilla with no deposits and f | a severely damaged papilla with numerous small 
deposits.
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Figure 6. Renal cortical changes in patients who formed calcium stones
Histopathology images showing a | moderate changes in the cortex of a patient who formed 
brushite stones, b | patchy change in the cortex of a patient who formed apatite stones, and c 
| minimal interstitial fibrosis and glomerulosclerosis in a patient who formed idiopathic 
CaOx stones.
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Figure 7. Effect of urine flow rate on calcium oxalate and calcium phosphate supersaturations
Urine supersaturations of calcium oxalate (CaOx) and calcium phosphate (CaP) varied 
inversely with urine flow rate in normal subjects (blue) and hypercalciuric idiopathic 
calcium stone formers (red) on the same diet. During fasting both a | CaOx and b |[ the 
figure is mislabeled, the y axis says CaOx, but should say CaP] CaP supersaturation values 
were generally high when urine flow was <100 ml/h. When urine flow was >100 ml/h many 
CaP supersaturation values were less than one, indicating that crystal formation will not 
occur. A much higher urine flow rate was required to reduce CaOx supersaturations to a 
similar level. When the participants were fed the distributions of c | CaOx and d | CaP 
supersaturations shifted to the right because of increased urinary excretion of calcium and 
oxalate. A urine flow rate of around 125 ml/h seems to be an appropriate clinical goal to 
prevent large increases in CaOx and CaP supersaturations. e and f | Although each 
participant provided only one urine sample overnight the general pattern of supersaturation 
and urine flow is similar to that seen during fasting. A goal of 100 ml/h urine flow overnight 
seems reasonable for stone prevention. Data from Bergsland et al. Am. J. Physiol Renal 
Physiol 297, F1017–F1023 (2009)76.
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